Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature
Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature
复制标题
DOI：
10.1111/ejh.12396
复制
发表时间：
2015-06-01
影响因子：
3.1
通讯作者：
Rieger, Christina T.
中科院分区：
文献类型：
--
作者：
Alig, Stefan K.;Dreyling, Martin;Rieger, Christina T.
维布妥昔单抗是一种靶向CD 30的抗体-药物偶联物。我们报告了一例64岁复发性系统性间变性大细胞淋巴瘤（sALCL）患者在维布妥昔单抗首次给药后发生重度细胞因子释放综合征（CRS）的病例。据我们所知，这是文献中描述的首例维布妥昔单抗CRS病例。然而，维布妥昔单抗的CRS可能被低估，因为该药物尚未在大型III期试验中进行测试。
Brentuximab Vedotin is an antibody - drug conjugate targeting CD30. We report a case of severe cytokine release syndrome (CRS) after administration of the first dose of Brentuximab Vedotin in a 64-yr-old patient with relapsed systemic anaplastic large cell lymphoma (sALCL). To our knowledge, this is the first case of CRS to Brentuximab Vedotin described in the literature. However, CRS to Brentuximab Vedotin might be underestimated, as the drug has not been tested in large phase III trials yet.